A Phase 1/2 Open-label Rolling-arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants With Melanoma (KEYMAKER-U02): Substudy 02A
Latest Information Update: 18 Jun 2025
At a glance
- Drugs Lenvatinib (Primary) ; Pembrolizumab (Primary) ; Quavonlimab (Primary) ; Vibostolimab (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms KEYMAKER-U02; MK-3475-02A; Substudy 02A
- Sponsors Merck Sharp & Dohme Corp.
Most Recent Events
- 04 Jun 2024 Preliminary Results (At data cutoff (Oct 18, 2022, n=40)presented at the 60th Annual Meeting of the American Society of Clinical Oncology
- 20 Dec 2023 Status changed from recruiting to active, no longer recruiting.
- 21 Sep 2021 Trial design presented at the 46th European Society for Medical Oncology Congress